Disclosure: We may have a financial affiliation with some entities featured on this page. Rankings are editorial; see our methodology.
Educational content — not medical advice. Menopause Brief is an independent educational publisher, not a clinic, pharmacy, or telehealth provider. We do not diagnose or prescribe.
The short version
If weight feels harder to move in perimenopause or after your final period, you are not imagining it. Estrogen decline is tied to more visceral fat, less lean mass, and shifts in glucose and energy handling. GLP-1 medicines and dual agonists such as tirzepatide are major tools for medical weight management. A separate question is whether MHT changes how well they work.
Here is a sourced read of what is known in mid-2026 — and what still needs better trials.
What menopause does to body composition
A 2026 clinical review summarizes a pattern: women tend to gain total and visceral fat while losing lean mass. MHT may help some candidates, but it is not a primary weight-loss treatment. Hormones do not replace nutrition, strength training, sleep, or appropriate obesity pharmacotherapy. Obesity Pillars review.
What GLP-1 research says
A 2026 Cureus review found associations with weight loss and reduced central adiposity in menopausal women. Larger menopause-specific trials are needed. Muscle preservation, protein, resistance training, and bone health deserve attention. Cureus review.
The MHT + GLP-1 signal: interesting, not proof
One semaglutide analysis reported greater loss with concurrent HT (roughly 16% versus 12% in summaries). A retrospective tirzepatide cohort reported −19.2% versus −14.0% mean loss for matched postmenopausal women with and without HT. Both are observational: selection bias, adherence, dose, and residual confounding prevent a prescription rule. Menopause journal study.
A trial to watch
NCT06715514 (DECLARED-CT) is registered and active, though not currently recruiting, to test estradiol plus a GLP-1RA versus GLP-1RA alone. Reconfirm live status on ClinicalTrials.gov before relying on it. MHT remains indication-driven, not a GLP-1 booster.
Practical takeaways
- GLP-1 therapy may help eligible patients; ask about muscle, bone, and nutrient status.
- MHT is individualized and supervised by licensed clinicians who know your history.
- When both are relevant, coordinated hormone and metabolic care may be easier to evaluate.
- Read FDA-approved versus compounded language carefully.
For a comparison of menopause weight and hormone programs, see our ranking.
Disclosure and medical disclaimer
Menopause Brief is an independent educational publisher. We may have a financial affiliation with some entities featured. This article is for education only, not medical advice, diagnosis, or treatment. We are not a medical provider, pharmacy, or telehealth clinic. Consult a licensed clinician.